- Principles of patient risk stratification for drug test frequency
- Impact of COVID 19 on risk assessment
- Use of confirmatory testing
- Drug test randomization strategies
- Vermont OBOT Stability Index tool
- Impact of MAT regulatory changes during the State of Emergency
* Tony Folland serves as the Clinical Services Manager and State Opioid Treatment Authority for the Vermont Department of Health, Division of Alcohol and Drug Abuse Programs and has been in State service since 2010. In the Vermont system of care, Tony has regulatory oversight of both the Hub (OTP) providers and DATA 2000 waivered prescribers. Prior to state government, he previously served for nearly 20 years as a clinician, program director and clinical director in various MH/SA organizations, both in rural and urban settings, and was both a Clinician and, subsequently, Clinical Director of Vermont’s initial Buprenorphine Induction Hub for several years. With regard to the current iteration of the Hub and Spoke System, Tony was honored to Chair the Medical provider development subcommittee, participating in the clinical assessment subcommittee and serving on the Clinical & Scientific Leadership Committee to develop the provider Learning Collaborative to support prescriber education and practice improvement.
At the conclusion of this learning collaborative, (at least 75% of) participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
For questions email the presenter: